Effect of a low dose of empagliflozin on short-term outcomes in type 2 diabetics with acute coronary syndrome after percutaneous coronary intervention

Abstract

‫دخول‬ ‫إعادة‬ ،)p=0.598 ‫%2.4؛‬ ‫مقابل‬ ‫األوعية‬ ‫تكوين‬ ‫وإعادة‬ ،)p=0.433 ‫%7.8)؛‬ ‫مقابل‬ 4.5%( ‫املستقرة‬ ‫غير‬ .)p=0.312 ‫%0؛‬ ‫مقابل‬ 2.2%( ‫التاجية‬ Objectives: To study the effects of low dose of empagliflozin on improving outcomes in diabetic patients with acute coronary syndrome )ACS( after percutaneous coronary intervention )PCI(. Methods: This double-blind controlled clinical trial was carried out on 93 diabetic patients )56 males and 37 females, mean age of 56.55 years( with ACS who underwent PCI at 2 university teaching hospitals in 2020, Ahvaz, Iran. The patients were randomly assigned to receive empagliflozin )10 mg once daily( or placebo at similar doses for 6 months after PCI. In addition, to standard treatments with another hypoglycemic agent. Cardiovascular outcomes )including all-cause mortality, coronary revascularization, rehospitalization due to unstable angina, hospitalization due to heart failure, Original Article cardiovascular death, non-fetal myocardial infarction, and non-fetal stroke( were evaluated during period of 6 months follow-up after the empagliflozin treatment. Results: There was no significant difference between the low dose empagliflozin and placebo groups after treatment in terms of cardiovascular mortality )2.2% versus [vs.] 4.2%; p=0.598(, rehospitalization due to unstable angina )4.5% vs. 8.7%; p=0.433(, and coronary revascularization )2.2% vs. 0%; p=0.312(. Conclusion:The results of this study showed that adding low dose empagliflozin to standard care of ACS diabetic patients after PCI was associated with no significant reduction in negative cardiovascular outcomes during 6 months.

Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Acute Coronary Syndrome

“…The study selection process is shown in Figure S1. We identified a total of 1483 records, and 25 reports were included in the final analysis. ,− Two publications were from the same original study and their data were pooled. , Thus, 24 studies, including 15 RCTs and 9 observational studies, were included. These studies were published between 2019 and 2023 and enrolled a total of 12,413 patients (6175 in the SGLT2i group and 6238 in the non-SGLT2i group).…”

Unraveling the Cardiac Matrix: From Diabetes to Heart Failure, Exploring Pathways and Potential Medications

“…However, long-term empagliflozin administration did not significantly improve LV function, shape, adiposity, or diffuse fibrosis in individuals with T2DM [ 142 ]. Similarly, no significant difference in mortality was observed between patients with diabetes receiving low-dose empagliflozin after percutaneous coronary intervention (PCI) for ACS and the placebo group [ 143 ]. Nonetheless, empagliflozin treatment improved heart function in mice with diabetes after infarction, particularly diastolic function, suggesting potential benefits in diabetic cardiomyopathy [ 144 ].…”

Update on evidence-based clinical application of sodium-glucose cotransporter inhibitors: Insight to uncommon cardiovascular disease scenarios in diabetes

“…There was no significant difference between the empagliflozin group and the placebo group in terms of post-treatment cardiovascular mortality (2.2% vs 4.2%; P = 0.598), rehospitalization for unstable angina (4.5% vs 8.7%; P = 0.433), or coronary revascularization (2.2% vs 0%; P = 0.312). The results of this study showed that the addition of empagliflozin to standard care after percutaneous coronary intervention in patients with T2D complicated with acute coronary syndrome did not significantly reduce cardiovascular outcomes within 6 mo[ 47 ].…”